T3 uptake: an indirect measure of free binding sites on thyroid-binding globulin
T3 uptake is a derived measure from a blood sample that estimates the carrying capacity of the blood for thyroid hormones. It does not measure triiodothyronine itself. Instead, it reflects how many binding sites on the blood’s thyroid hormone carrier proteins are available or already occupied. These carriers—mainly thyroxine‑binding globulin (TBG), with contributions from transthyretin and albumin—are made in the liver and ferry thyroid hormones (T4 and T3) through the circulation.
Its significance is that it captures the balance between bound hormone and the portion that can circulate freely and reach tissues. Because most thyroid hormone travels attached to carrier proteins, shifts in those proteins can make total hormone numbers misleading. T3 uptake helps correct for that. Used alongside a total T4, it contributes to an estimate of free thyroxine availability to cells (free thyroxine index, FTI). In short, T3 uptake is a window into the bloodstream’s thyroid hormone–binding environment, clarifying how much hormone is effectively accessible to the body.
Why T3 uptake helps separate true thyroid disease from binding-protein noise
T3 uptake doesn’t measure T3 itself; it gauges how “full” the thyroid‐hormone transport proteins are in your blood. That makes it a window into how much of your circulating thyroid hormone is free to act on cells versus carried by proteins—key for energy use, temperature control, heart rhythm, mood, and growth.
Big picture: T3 uptake is most informative alongside total T4 (to estimate the free thyroxine index) or with TSH/free T4. It helps separate true thyroid dysfunction from shifts in binding proteins, linking thyroid status to liver, kidney, and sex‑hormone physiology and to long‑term risks in heart, bone, fertility, and cognition.
What low, normal, and high T3 uptake values are telling you
Results are reported as a percentage or index. Because labs use different methods, each lab supplies its own range; values near the middle usually reflect a balanced binding capacity and free hormone availability.
When the value is low, there are many open binding sites—often because the main carrier (thyroxine‑binding globulin, TBG) is high, or because the thyroid is underactive. Physiology tilts toward less free hormone at the tissue level. People may feel slowed: fatigue, feeling cold, constipation, dry skin, heavier periods, higher LDL, and a slower pulse; children can show slowed growth and learning. Pregnancy and estrogen therapy commonly lower the result by raising TBG, even when true thyroid function is normal.
When the value is high, there are fewer open sites—often from low TBG or excess thyroid hormone. If due to hyperthyroidism, metabolism speeds up: heat intolerance, weight loss, tremor, anxiety, palpitations, lighter or irregular periods, and bone loss risk; older adults may develop atrial fibrillation. Low TBG states (androgens, protein loss) can also raise it without true overactive thyroid.
When estrogens, androgens, and illness shift T3 uptake
Notes: Estrogens (including pregnancy) lower uptake; androgens, nephrotic syndrome, and some illnesses raise it by lowering TBG. Modern practice often relies on free T4 and TSH, using T3 uptake mainly to compute the Free Thyroxine Index or to assess binding protein effects.
T3 uptake's place alongside TSH, free T4, and FTI
The T3 uptake (T3 resin uptake) does not measure T3 itself. It estimates how many thyroid‑hormone binding sites on blood proteins—mainly thyroxine‑binding globulin (TBG)—are unoccupied. By indicating the balance between binding proteins and circulating thyroid hormone, it helps infer how much free hormone is available to drive energy production, metabolism, heart rate, temperature regulation, cognition, and reproductive and immune function. It is often paired with total T4 to calculate the Free Thyroxine Index.
Low values usually reflect many unfilled binding sites, most often from increased TBG or too little thyroid hormone (hypothyroxinemia). If free hormone is truly low, systems slow: reduced metabolic rate, fatigue, cold intolerance, bradycardia, constipation, heavier menses, and cognitive slowing. In pregnancy or with higher estrogen states, TBG rises and T3 uptake falls, yet tissue thyroid hormone can remain normal.
Being in range suggests a balanced relationship between binding proteins and thyroid hormone, supporting stable delivery of free T4/T3 to tissues and steady metabolic, cardiovascular, and neurocognitive function. In many settings, mid‑range values align with euthyroid status and normal TBG.
High values usually reflect few available binding sites, seen with low TBG or with abundant thyroid hormone saturating those sites (hyperthyroxinemia). If free hormone is high, systems speed up: heat intolerance, palpitations, anxiety, tremor, and weight loss. With low TBG states, thyroid status may be normal despite a high uptake.
FAQs
T3 Uptake measures the availability of thyroid-hormone binding sites on serum proteins (mainly TBG). It does not measure T3 itself and is used to help calculate the Free Thyroxine Index (FTI).
T3 Uptake clarifies whether abnormal total T4/T3 reflect true thyroid dysfunction or shifts in binding proteins. It adds key context during pregnancy, with estrogen therapy, exposure to androgens or steroids, and in protein-losing states.
Consider testing when starting or stopping estrogen or androgens, during pregnancy, when thyroid results conflict with symptoms, or when tracking known binding-protein changes over time.
Estrogens raise TBG and can lower T3 Uptake. Androgens, anabolic steroids, glucocorticoids, and protein-losing states lower TBG and can raise T3 Uptake. Liver, kidney, and nutritional factors can also influence binding proteins.
Most T3 Uptake tests do not require special preparation. Follow the specific instructions provided with your lab test to helps support consistent, reliable results.
Superpower currently offers at-home blood testing in the following states: Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Kansas, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, and Wisconsin.
We’re actively expanding nationwide, with new states being added regularly. If your state isn’t listed yet, stay tuned.
References
- Köhrle, J. (2018). Thyroid hormones and derivatives: Endogenous thyroid hormones and their targets. Methods in Molecular Biology, 1801, 85-104. https://doi.org/10.1007/978-1-4939-7902-8_9
- Koulouri, O., Moran, C., Halsall, D., Chatterjee, K., & Gurnell, M. (2013). Pitfalls in the measurement and interpretation of thyroid function tests. Best Practice & Research. Clinical Endocrinology & Metabolism, 27(6), 745-762. https://doi.org/10.1016/j.beem.2013.10.003
- Russo, S. C., Salas-Lucia, F., & Bianco, A. C. (2021). Deiodinases and the metabolic code for thyroid hormone action. Endocrinology, 162(8), bqab059. https://doi.org/10.1210/endocr/bqab059
- Chaker, L., Bianco, A. C., Jonklaas, J., & Peeters, R. P. (2017). Hypothyroidism. Lancet, 390(10101), 1550-1562. https://doi.org/10.1016/S0140-6736(17)30703-1
- Garber, J. R., Cobin, R. H., Gharib, H., Hennessey, J. V., Klein, I., Mechanick, J. I., Pessah-Pollack, R., Singer, P. A., & Woeber, K. A. (2012). Clinical practice guidelines for hypothyroidism in adults: Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid, 22(12), 1200-1235. https://doi.org/10.1089/thy.2012.0205






































.avif)
